ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Cutaneous"

  • Abstract Number: 0598 • ACR Convergence 2021

    Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study

    Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…
  • Abstract Number: 0970 • ACR Convergence 2021

    Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes

    Grace Hile1, Patrick Coit2, Bin Xu1, Shannon Estadt1, Jacob Martens3, Rachael Wasikowski1, Lam Tsoi1, Ramiro Iglesias-Bartolome4, Celine Berthier1, Allison Billi5, Johann Gudjonsson5, Amr Sawalha2 and J. Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI, 2University of Pittsburgh, Pittsburgh, PA, 3Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, 4NIH, National Cancer Institute, Bethesda, MD, 5Department of Dermatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
  • Abstract Number: 1043 • ACR Convergence 2021

    Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study

    Mehmet Hocaoglu1, Mark Davis2, Maria Valenzuela-Almada3, Jesse Dabit2, Shirley-Ann Osei-Onomah2, Sebastian Vallejo-Ramos2, Tina Gunderson2, Kurt Greenlund4, Kamil Barbour4, Cynthia Crowson5 and Ali Duarte-Garcia2, 1University of Maryland Medical Center, Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Centers for Disease Control, Atlanta, GA, 5Mayo Clinic, Eyota, MN

    Background/Purpose: Cutaneous lupus erythematosus (CLE) patients report impaired quality of life due to cutaneous and psychological morbidity. Previous literature on the prevalence of comorbidities in…
  • Abstract Number: 1282 • ACR Convergence 2021

    Classification of Disease Activity and Damage in Cutaneous Lupus

    Laila Abbas, Karabi Nandy and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The Cutaneous Lupus Disease Area and Severity Index (CLASI) can quantify disease activity and damage in Cutaneous Lupus Erythematosus (CLE). Classification of CLASI scores…
  • Abstract Number: 1491 • ACR Convergence 2021

    Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types

    Allison Billi1, Feiyang Ma2, Olesya Plazyo3, Grace Hile3, Xianying Xing3, Mehrnaz Gharaee-Kermani4, Rachael Wasikowski3, Lam Tsoi3, Matteo Pellegrini2, Robert L. Modlin2, Johann Gudjonsson1 and J. Michelle Kahlenberg3, 1Department of Dermatology, University of Michigan, Ann Arbor, MI, 2University of California Los Angeles, Los Angeles, CA, 3University of Michigan, Ann Arbor, MI, 4Internal Medicine - Division of Rheumatology and Department of Dermatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is an incompletely understood autoimmune disease that can occur in isolation or in the context of SLE. CLE is often…
  • Abstract Number: 1495 • ACR Convergence 2021

    Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials

    Thomas Vazquez1, Jay Patel2, Daisy Yan3, Emily Keyes4, DeAnna Diaz5, Yubin Li6, Madison Grinnell6, Rui Feng7 and Victoria Werth3, 1FIU Wertheim College of Medicine, Virginia Beach, VA, 2Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 5Philadelphia College of Medicine, Philadelphia, PA, 6Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, 7University of Pennsylvania Department of Biostatistics, Philadelphia, PA

    Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…
  • Abstract Number: 0278 • ACR Convergence 2020

    Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study

    Mehmet Hocaoglu1, Mark Denis P. Davis2, Shirley-Ann Osei-Onomah3, Jesse Dabit2, Rachel Giblon2, Thomas O'Byrne2, Cynthia Crowson4 and Ali Duarte-Garcia2, 1University of Maryland Medical Center Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous chronic disease with potential for long lasting morbidity. Studies that provide incidence data on the entire spectrum…
  • Abstract Number: 0300 • ACR Convergence 2020

    Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin

    Sirisha Sirobhushanam1, Allison Billi2, Alex Tsoi2, Celine Berthier2, Johann Gudjonsson3 and J. Michelle Kahlenberg4, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, 3University of Michigan, Ann ArborUniversity of Michigan, 4Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
  • Abstract Number: 0985 • ACR Convergence 2020

    Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies

    Victoria Werth1, Richard Furie2, Eric Morand3, J. Michelle Kahlenberg4, Rubana Kalyani5, Gabriel Abreu6, Lilia Pineda5 and Raj Tummala5, 1University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia, 2Zucker School of Medicine at Hofstra/Northwell, Great Neck, 3Monash University, Melbourne, Australia, 4Division of Rheumatology, University of Michigan, Ann Arbor, MI, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Up to 85% of patients with SLE experience skin disease.1 The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated index…
  • Abstract Number: 0986 • ACR Convergence 2020

    BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus

    Victoria Werth1, Richard Furie2, Juanita Romero-Díaz3, Sandra Navarra4, Kenneth Kalunian5, Ronald van Vollenhoven6, Filippa Nyberg7, Benjamin Kaffenberger8, Saira Sheikh9, Goran Radunovic10, Xiaobi Huang11, Hua Carroll12, Francois Gaudreault12, Adam Meyers11, Catherine Barbey13, Cristina Musselli11 and Nathalie Franchimont11, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 3Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 4University of Santo Tomas, Manila, Philippines, 5University of California San Diego, La Jolla, CA, 6Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 7Karolinska University Hospital, Stockholm, Sweden, 8Ohio State University, Columbus, OH, 9Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, 10Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, 11Biogen, Cambridge, MA, 12Biogen, Cambridge, 13Biogen, Baar, Switzerland

    Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…
  • Abstract Number: 1065 • ACR Convergence 2020

    Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis

    Adarsh Ravishankar1, Daisy Yan2, Christina Bax3, Josef Symon Concha2, Bridget Shields4, Lisa Pappas-Taffer4, Rui Feng5, Joyce Okawa4 and Victoria Werth2, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 5University of Pennsylvania, Philadelphia

    Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been…
  • Abstract Number: 1982 • ACR Convergence 2020

    Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus

    Josef Symon Concha1, Daisy Yan1, Christina Bax2, Adarsh Ravishankar3, Robert Borucki4, Rui Feng4 and Victoria Werth5, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2University of Pennsylvania, Department of Dermatology, Philadelphia, 3University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 4University of Pennsylvania, Philadelphia, 5University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia

    Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…
  • Abstract Number: 1989 • ACR Convergence 2020

    NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin

    Jessica Turnier1, Lauren Pachman2, Lori Lowe3, Alex Tsoi3, Sultan Elhaj1, Rajasree Menon1, Maria Amoruso2, Gabrielle Morgan4, Johann Gudjonsson5, Celine Berthier3 and J Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3University of Michigan, Ann Arbor, 4Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 5University of Michigan, Ann ArborUniversity of Michigan

    Background/Purpose: Skin inflammation can herald systemic disease in juvenile myositis (JM), yet we lack an understanding of pathogenic mechanisms driving skin inflammation in JM. The…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies